Providing over-the-counter vaginal oestrogen in New Zealand: a cross-sectional study of pharmacists’ views
The Journal of Primary Health Care · 26.03.2026 · 18 (1) · 45-52
DOI: 10.1071/hc25065 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift The Journal of Primary Health Care, online erschienen am 05.08.2025. Verfasst von Tylah Maniapoto und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy | He Rau Kawakawa, University of Otago | Ōtākou Whakaihu Waka, Adams Building, 18 Frederick Street, PO Box 56, Dunedin, 9054, New …. Hauptthemen laut MEDLINE: Nonprescription Drugs, Pharmacists, Estrogens, Attitude of Health Personnel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Genitourinary symptoms of menopause (GSM) affect a large proportion of women and can worsen over time if left untreated. In New Zealand, effective treatment with low-dose vaginal oestrogen is available only by prescription, limiting timely access. Internationally, such treatments have been reclassified for supply by pharmacists, but there are no studies examining New Zealand pharmacists’ perspectives on this.
Aim
This study aimed to determine pharmacists’ confidence in treating GSM and their perspectives on supplying an over-the-counter (OTC) vaginal oestrogen.
Methods
A cross-sectional survey was distributed by the research team to 2762 registered pharmacists. The survey explored confidence in GSM management, opinions on OTC vaginal oestrogen supply, perceptions of patient preferences, and barriers and facilitators to service delivery. Quantitative data were analysed descriptively, and open-ended responses were reviewed using descriptive thematic analysis.
Results
A total of 299 pharmacists responded (response rate 10.8%). While only 46.8% felt confident in recommending currently available OTC products for GSM, 61.2% reported they would be confident supplying low-dose vaginal oestrogen OTC. Pharmacists believed that supplying OTC oestrogen would improve accessibility, reduce the burden on general practice, and support patient-centred care. Key barriers included cost to patients, lack of specific knowledge of GSM, and limited time or resources in the pharmacy setting.
Discussion
Pharmacists in New Zealand support expanding their role to supply low-dose OTC vaginal oestrogen for GSM, provided that appropriate tools and training are implemented. This service could improve access, address health disparities, and significantly enhance menopause care in New Zealand.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy | He Rau Kawakawa, University of Otago | Ōtākou Whakaihu Waka, Adams Building, 18 Frederick Street, PO Box 56, Dunedin, 9054, New Zealand | Aotearoa.
ORCID-Profile: Amber Young, Alesha Smith
Zitieren
APA
Maniapoto, T., Young, A., & Smith, A. (2026). Providing over-the-counter vaginal oestrogen in New Zealand: a cross-sectional study of pharmacists’ views. The Journal of Primary Health Care, 18(1), 45-52. https://doi.org/10.1071/hc25065
Vancouver
Maniapoto T, Young A, Smith A. Providing over-the-counter vaginal oestrogen in New Zealand: a cross-sectional study of pharmacists’ views. The Journal of Primary Health Care. 2026;18(1):45-52. doi:10.1071/hc25065
BibTeX
@article{Maniapoto2026,
author = {Maniapoto, Tylah and Young, Amber and Smith, Alesha},
title = {Providing over-the-counter vaginal oestrogen in New Zealand: a cross-sectional study of pharmacists’ views},
journal = {The Journal of Primary Health Care},
year = {2026},
volume = {18},
number = {1},
pages = {45--52},
doi = {10.1071/hc25065}
}
EUVIMED